登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma
ClinicalTrials.gov 上登记的一项胶质瘤开放试验,由首都医科大学附属北京天坛医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07873996,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 65 岁;性别:不限
登记记录的入选字段
Newly diagnosed postoperative glioblastoma confirmed by histopathology or molecular pathology as WHO CNS grade 4 glioblastoma, IDH-wildtype, according to the 2021 WHO Classification of Central Nervous System Tumors.
入选标准第 3 条
Karnofsky Performance Status (KPS) score of at least 70 within 1 week before PBMC collection and within 4 days before Tris-CAR-T cell infusion.
入选标准第 9 条
At least one preoperative measurable lesion meeting RANO 2.0 criteria outside the radiation field, with the longest diameter of the measurable lesion no greater than 3 cm by imaging assessment.
入选标准第 5 条
HBsAg positive with HBV DNA positive, HCV antibody positive with HCV RNA positive, Treponema pallidum antibody positive, or HIV antibody positive.
排除标准第 16 条
For female participants of childbearing potential, negative pregnancy tests within 2 weeks before PBMC collection and within 1 week before the first CAR-T cell infusion. Participants of childbearing potential, male or female, must agree to use effective medical contraception from screening through 2 years after the last cell infusion.
入选标准第 13 条
Pregnant or lactating female.
排除标准第 18 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07873996,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily signs written informed consent. 18 to 65 years of age, inclusive, male or female. Newly diagnosed postoperative glioblastoma confirmed by histopathology or molecular pathology as WHO CNS grade 4 glioblastoma, IDH-wildtype, according to the 2021 WHO Classification of Central Nervous System Tumors. Tumor tissue positive for CD44 or CD133 antigen expression by immunohistochemistry, defined as CD44 or CD133 staining positive in at least 1% of tumor cells, regardless of staining intensity. At least one preoperative measurable lesion meeting RANO 2.0 criteria outside the radiation field, with the longest diameter of the measurable lesion no greater than 3 cm by imaging assessment. No prior radiotherapy and no prior treatment with temozolomide, bevacizumab, or other anti-tumor therapy for glioblastoma. Confirmed by the investigator to be suitable for Ommaya reservoir implantation. Adequate venous access for peripheral blood mononuclear cell collection. Karnofsky Performance Status (KPS) score of at least 70 within 1 week before PBMC collection and within 4 days before Tris-CAR-T cell infusion. Expected survival of at least 3 months. Adequate bone marrow, hepatic, renal, coagulation, and oxygenation function within 1 week before PBMC collection and within 1 week before Tris-CAR-T cell infusion, including HGB at least 100 g/L, WBC at least 3.5 × 10\^9/L, ANC at least 1.5 × 10\^9/L, PLT at least 100 × 10\^9/L, lymphocyte count greater than 1 × 10\^9/L, ALT and AST no more than 2.5 × ULN, TBIL no more than 1.5 × ULN, creatinine no more than 1.5 × ULN, PT or INR no more than 1.5 × ULN, APTT no more than 1.5 × ULN, and resting oxygen saturation without oxygen at least 95%. Left ventricular ejection fraction greater than 50% and electrocardiogram QTcF no more than 480 msec within 14 days before PBMC collection and within 14 days before Tris-CAR-T cell infusion. For female participants of childbearing potential, negative pregnancy tests within 2 weeks before PBMC collection and within 1 week before the first CAR-T cell infusion. Participants of childbearing potential, male or female, must agree to use effective medical contraception from screening through 2 years after the last cell infusion. Willing and able to comply with protocol-specified visits, study treatment, laboratory tests, and other study-related requirements.排除标准:Exclusion Criteria:
Autologous CAR-T cell manufacturing cannot be completed or the CAR-T cell product does not meet clinical use requirements. Highly allergic constitution, history of severe allergy, or allergy to related cell products. Receipt of approved or investigational anti-tumor therapy within 2 weeks before PBMC collection or within 5 half-lives of the therapy, whichever is longer, including but not limited to chemotherapy, radiotherapy, surgery other than diagnostic surgery, targeted therapy, cell infusion therapy, hormone therapy other than hormone replacement therapy, or traditional Chinese medicine with a clear anti-tumor indication; a 1-week washout is acceptable for traditional Chinese medicine. Severe clinical infection greater than Grade 2 by NCI CTCAE v6.0 within 2 weeks, uncontrolled active infection, or unexplained fever before PBMC collection or Tris-CAR-T cell infusion. Prior anti-tumor treatment-related adverse reactions have not recovered to Grade 1 or lower by NCI CTCAE v6.0, except alopecia, skin pigmentation, leukoplakia, or other findings judged by the investigator to pose no safety risk. Tumor lesion metastasis to the brainstem or spinal cord. Serious neurological diseases other than the brain tumor, such as meningitis, encephalitis, myelitis or demyelinating disease, myasthenic syndrome or myasthenia gravis, amyotrophic lateral sclerosis, spinal muscular atrophy, nerve palsy, or uncontrolled epilepsy. Myocardial infarction, coronary artery bypass grafting, coronary angioplasty, coronary stent implantation, pulmonary embolism, new arterial or deep venous thrombosis, stroke, or transient ischemic attack within 6 months, excluding brain tumor bleeding or brain tumor surgery-related bleeding. Heart failure NYHA class 2 or higher, myocarditis, cardiomyopathy, pericarditis, cardiac valve morphological abnormality Grade 2 or higher, unstable coronary heart disease, poorly controlled hypertension with systolic blood pressure at least 150 mmHg or diastolic blood pressure at least 100 mmHg, or severe arrhythmia or conduction abnormality requiring medication. Severe respiratory disease requiring treatment, such as pneumonia, chronic bronchitis, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, interstitial lung disease, or respiratory failure. Hepatitis requiring treatment, uncontrolled or unstable liver function impairment, or diabetes mellitus not controlled with medication. Severe urinary system disease or abnormality requiring treatment, such as proteinuria, glomerulonephritis, or renal function abnormality. Primary immunodeficiency disease, autoimmune disease requiring medication, such as Crohn disease, ulcerative colitis, rheumatoid arthritis, or systemic lupus erythematosus, or history of neurological autoimmune disease such as multiple sclerosis or Parkinson disease. Receiving or requiring long-term immunosuppressive therapy, except physiologic systemic corticosteroid replacement equivalent to prednisone 10 mg/day or less, short-term corticosteroids for no more than 7 days for prevention or treatment of non-autoimmune allergic disease, or topical, intra-articular, intranasal, inhaled, or other local glucocorticoids. Prior allogeneic bone marrow transplantation or organ transplantation, or awaiting organ transplantation. HBsAg positive with HBV DNA positive, HCV antibody positive with HCV RNA positive, Treponema pallidum antibody positive, or HIV antibody positive. Prior gene therapy or cell therapy. Pregnant or lactating female. History of malignancy other than glioma within 5 years, except adequately treated carcinoma in situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, localized prostate cancer, or stage I cervical cancer judged by the investigator to have very low risk of recurrence. Any other disease, abnormal test result, psychiatric factor, or social factor that may affect compliance with protocol procedures, place the participant at high risk when receiving the investigational product, or interfere with interpretation of study results, making the participant unsuitable for this clinical study in the investigator's judgment.
引自 ClinicalTrials.gov, NCT07873996, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07873996,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。